293 



19 5 2 



770. ALGIRE, G. H., LEGALIAIS, F. Y. and AmDERSON, B. F. 



Vascular reactions of normal and malignant tissues in vivo . V. The 

 role of hypotension in the action of a bacterial polysaccharide on tumors 



J. Nat. Cancer Inst-. 12:1279-1291, 1952 



Peripheral or intratumoral circulation restriction by mechanical means 

 (occlusion) or biochemical substances (histamine, bacterial carbohydrate 

 complexes), is followed by damage or regression in tumor tissue. Retarded 

 blood flow and resultant stasis and tissue anoxia, ajid not a direct cyto- 

 toxic effect, underlie these tissue changes. 



"In mice bearing rapidly growing strain L and sarcoma 37 implants, h;>'po- 

 tension was produced in neoplastic tissue l>y single or repeated injections 

 of bacterial polysaccharides obtained from S. marcescens culture filtrates 

 (P-10, P-20 and P-25 of Shear). Systolic pressure \jas observed micro- 

 scopically in arteries adjacent to tumors and capillary changes within 

 tumor tissue were noted. In vivo criteria of tumor damage were supple- 

 mented by histologic studies of excised tissue. Hj'potension, in both de- 

 gree and duration, correlates to the dosage administered to normal or tiimor- 

 bearing animals. No vascular changes were observed in the absence of hypo- 

 tension. The functional capillaries within the tumor were reduced in ex- 

 tent after the initial dose of the bacterial polysaccharide (by approxi- 

 mately 80^). Circulation \ra.s retarded within the first hour following 

 administration. White thrombi were observed after 5 hours. In 2k hours, 

 the center of the tumor was opaque and necrosis followed within 5 days. 

 The most pronounced and prolonged fall in blood pressure was produced by 

 the initial injection of the polysaccharide; succeeding injections may pro- 

 voke resistance to the tumor-necrotizing effects. 



771. BAILEY, A. A., ROOKE, E. D. and RODIN, E. A. 



Investigation of a bacterial pyrogen as a therapeutic agent in neurologic 

 disorders 



Proc. Staff Meet. Mayo Clinic 27:5lj-0-3l^5, 1952 



PIROMEN was employed as a therapeutic agent for 57 patients exhibiting 

 disease entities in ■vrfiich it was desirable to inhibit the formation of 

 scar tissue and to promote the regeneration of neurons and axones. The 

 product vras given in dosages ranging between 2 and 9 micrograms, for 

 limited periods, in the treatment of amyotrophic and multiple sclerosis, 

 traumatic and retrobulbar neuritis, neuronitis, traumatic paraplegia, 

 arachnoiditis and central nervous system involvements of indeterminate 

 types. Its effect on residual evidences of poliomyelitis was also determined. 



